Press Releases

Filter Releases

Date	Title and Summary	View
Toggle SummaryNov 05, 2013	Onconova Therapeutics, Inc. Announces Timing for Third Quarter 2013 Financial Results and Conference Call	View HTML Onconova Therapeutics, Inc. Announces Timing for Third Quarter 2013 Financial Results and Conference Call 12.7 KB
Toggle SummarySep 06, 2013	Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results	View HTML Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results 24 KB
Toggle SummaryJul 30, 2013	Onconova Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option	View HTML Onconova Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option 14.3 KB
Toggle SummaryJul 29, 2013	Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors	View HTML Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors 14.3 KB
Toggle SummaryJul 25, 2013	Onconova Announces Pricing of Initial Public Offering	View HTML Onconova Announces Pricing of Initial Public Offering 13.4 KB
Toggle SummaryJun 14, 2013	Onconova Files Registration Statement for Proposed Initial Public Offering of Common Stock	View HTML Onconova Files Registration Statement for Proposed Initial Public Offering of Common Stock 13.8 KB
Toggle SummaryJun 01, 2013	Onconova Announces Presentation of Favorable Safety and Activity Data from Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes Interim Results Presented at 2013 ASCO Annual Meeting Indicate Strong Signal of Transfusion Independence	View HTML Onconova Announces Presentation of Favorable Safety and Activity Data from Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes 18.5 KB
Toggle SummaryMay 15, 2013	Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting	View HTML Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting 14.3 KB
Toggle SummaryMay 09, 2013	Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes	View HTML Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes 15.4 KB
Toggle SummaryApr 09, 2013	Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting Oral Rigosertib Progresses to Phase 2 Clinical Trial in Squamous Cell Head and Neck Cancers	View HTML Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting 17 KB
Toggle SummaryApr 02, 2013	Onconova Appoints Ajay Bansal as Chief Financial Officer	View HTML Onconova Appoints Ajay Bansal as Chief Financial Officer 14.5 KB
Toggle SummaryJan 09, 2013	GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer	View HTML GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer 14.8 KB
Toggle SummaryDec 10, 2012	Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting Three Trials Demonstrate Safety and Tolerability in Hematological Malignancies	View HTML Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting 17.3 KB
Toggle SummaryOct 09, 2012	Onconova Appoints Dr. Thomas J. McKearn as President, Research and Development	View HTML Onconova Appoints Dr. Thomas J. McKearn as President, Research and Development 13.5 KB
Toggle SummaryOct 03, 2012	Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD®	View HTML Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD® 16.8 KB